IQuity Research Unveils Potential $18 Billion in Health Plan Cost-Savings and Demonstrates Effectiveness of Identifying At-Risk Autoimmune Disease Patients
IQuity announced that the company was published in a peer-reviewed article in the Journal of Clinical Medicine. This work is one of the first comprehensive overviews of prevalence, clinical characteristics, challenges, and financial impacts of […]
IQuity announced that the company was published in a peer-reviewed article in the Journal of Clinical Medicine. This work is one of the first comprehensive overviews of prevalence, clinical characteristics, challenges, and financial impacts of autoimmune diseases and related disorders (multiple sclerosis, ulcerative colitis, Crohn’s disease and rheumatoid arthritis, irritable bowel syndrome and fibromyalgia syndrome). These six conditions alone affect approximately 60 million people at an estimated cost to diagnose and treat of $90B annually.
